Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Minmin Kong

Xiquan Zhang

Aiming Zhang

Wenwei Xu

Shufeng Wu

Mingming Li

The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)&#x2014;N&#x2014;((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40&#xb0;, 20.28&#xb0;, 20.94&#xb0;, 22.02&#xb0;, and 24.46&#xb0;, represented by 2&#x3b8;. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value. 

Crystalline sulfamide compound

Growing community of inventors

Lianyungang, China

Minmin Kong